Literature DB >> 24927808

Irradiated tumor cells of lipopolysaccharide stimulation elicit an enhanced anti-tumor immunity.

Yuli Li1, Guobo Shen, Wen Nie, Zhimian Li, Yaxiong Sang, Binglan Zhang, Yuquan Wei.   

Abstract

PURPOSE: Lipopolysaccharide (LPS) is a major component of the outer surface membrane of Gram-negative bacteria which has been proved an effective immune enhancer. Here, we investigated the anti-tumor effect of irradiated tumor cells that stimulated by LPS in mouse xenografts models.
METHODS: Tumor cells were irradiated after stimulation with 1 μg/mL LPS for 48 h. The C57BL/6 mice were immunized subcutaneously with irradiated tumor cells. The anti-tumor effect of lymphocytes of immunized mice was investigated. The cytotoxicity of spleen lymphocytes from immunized mice was determined by a standard (51)Cr-release assay. The roles of immune cell subsets in anti-tumor activity were assessed by injected intraperitoneally with monoclonal antibodies.
RESULTS: We observed that the vaccine of irradiated tumor cell with LPS-stimulated elicited a stronger protective anti-tumor immunity than other controls. Adoptive transfer of lymphocytes of immunized mice showed that the cellular immune response was involved in the anti-tumor effect. And this effect was achieved by activation of antigen-specific CD8(+) T cell response and reduction of myeloid-derived suppressor cells (MDSCs, Gr1(+) CD11b (+) ), which were confirmed by depletion of immune cell subsets and flow cytometry analysis.
CONCLUSIONS: In summary, our study showed that stimulation of LPS was able to enhance anti-tumor immunity of vaccination with tumor cells after irradiation treatment, which might be a new strategy for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24927808     DOI: 10.1007/s00432-014-1721-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  40 in total

1.  Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.

Authors:  You Lu; Yu-quan Wei; Ling Tian; Xia Zhao; Li Yang; Bin Hu; Bin Kan; Yan-jun Wen; Feng Liu; Hong-xin Deng; Jiong Li; Yong-qiu Mao; Song Lei; Mei-juan Huang; Feng Peng; Yu Jiang; Hao Zhou; Li-qun Zhou; Feng Luo
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

Review 2.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

3.  Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.

Authors:  Martin K Hunn; Kathryn J Farrand; Kate W R Broadley; Robert Weinkove; Peter Ferguson; Rose J Miller; Cameron S Field; Troels Petersen; Melanie J McConnell; Ian F Hermans
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

4.  Involvement of MAPKs and NF-kappaB in LPS-induced VCAM-1 expression in human tracheal smooth muscle cells.

Authors:  Wei-Ning Lin; Shue-Fen Luo; Chiang-Wen Lee; Chien-Chun Wang; Jong-Shyan Wang; Chuen-Mao Yang
Journal:  Cell Signal       Date:  2007-01-19       Impact factor: 4.315

5.  A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha.

Authors:  H M Horton; D Anderson; P Hernandez; K M Barnhart; J A Norman; S E Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

6.  Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature.

Authors:  H J Mauceri; N N Hanna; J D Wayne; D E Hallahan; S Hellman; R R Weichselbaum
Journal:  Cancer Res       Date:  1996-10-01       Impact factor: 12.701

Review 7.  DNA vaccines: developing new strategies against cancer.

Authors:  Daniela Fioretti; Sandra Iurescia; Vito Michele Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-03-28

8.  Inhibition of antibody production in vivo by pre-stimulation of Toll-like receptor 4 before antigen priming is caused by defective B-cell priming and not impairment in antigen presentation.

Authors:  Nurlaely Mida Rachmawati; Kenji Fukudome; Naoko Tsuneyoshi; Uleng Bahrun; Hiroki Tsukamoto; Tsutomu Yanagibashi; Yoshinori Nagai; Kiyoshi Takatsu; Shoichiro Ohta; Masao Kimoto
Journal:  Int Immunol       Date:  2012-10-17       Impact factor: 4.823

9.  Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.

Authors:  Pankaj Agarwalla; Zachary Barnard; Peter Fecci; Glenn Dranoff; William T Curry
Journal:  J Immunother       Date:  2012-06       Impact factor: 4.456

10.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

View more
  2 in total

1.  Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity.

Authors:  Xiyan Mu; Chunju Fang; Jing Zhou; Yufeng Xi; Li Zhang; Yuquan Wei; Tao Yi; Yang Wu; Xia Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-03       Impact factor: 4.553

2.  Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer Immunotherapy.

Authors:  Min Luo; Bin Shao; Wen Nie; Xia-Wei Wei; Yu-Li Li; Bi-Lan Wang; Zhi-Yao He; Xiao Liang; Ting-Hong Ye; Yu-Quan Wei
Journal:  Sci Rep       Date:  2015-06-22       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.